Evidence map›Paper›PMID 37340093›Full record

ArticleBritish journal of cancer2023

PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia.

Gábor Bedics, Bálint Egyed, Lili Kotmayer, Anne Benard-Slagter, Karel de Groot, Anna Bekő, Lajos László Hegyi, Bence Bátai, Szilvia Krizsán, Gergely Kriván and 24 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. [Research progress on copy number alterations in pediatric B-cell acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 8 institutions in 3 countries.

Gábor Bedics *HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Bálint Egyed *HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Lili KotmayerHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Anne Benard-SlagterMRC Holland, Amsterdam, The Netherlands.ORCID 0009-0002-1897-1422
Karel de GrootMRC Holland, Amsterdam, The Netherlands.
Anna BekőHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Lajos László HegyiHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Bence BátaiHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Szilvia KrizsánHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Gergely KrivánCentral Hospital of Southern Pest - National Institute of Hematology and Infectious Diseases, Budapest, Hungary.
Dániel J ErdélyiDepartment of Pediatrics, Semmelweis University, Budapest, Hungary.
Judit MüllerDepartment of Pediatrics, Semmelweis University, Budapest, Hungary.
Irén HaltrichDepartment of Pediatrics, Semmelweis University, Budapest, Hungary.
Béla KajtárDepartment of Pathology, University of Pécs Medical School, Pécs, Hungary.ORCID 0000-0001-5551-3709
László PajorDepartment of Pathology, University of Pécs Medical School, Pécs, Hungary.
Ágnes VojcekDepartment of Pediatrics, University of Pécs Medical School, Pécs, Hungary.
Gábor OttóffyDepartment of Pediatrics, University of Pécs Medical School, Pécs, Hungary.
Anikó UjfalusiDepartment of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
István SzegediDivision of Pediatric Hematology-Oncology, Institute of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Lilla Györgyi TiszlaviczDepartment of Paediatrics and Paediatric Health Care Center, Faculty of Medicine, University of Szeged, Szeged, Hungary.
Katalin BartyikDepartment of Paediatrics and Paediatric Health Care Center, Faculty of Medicine, University of Szeged, Szeged, Hungary.
Krisztina CsanádiHemato-Oncology Unit, Heim Pál Children's Hospital, Budapest, Hungary.
György PéterHemato-Oncology Unit, Heim Pál Children's Hospital, Budapest, Hungary.
Réka SimonHemato-Oncology and Stem Cell Transplantation Unit, Velkey László Children's Health Center, Miskolc, Hungary.
Péter HauserHemato-Oncology and Stem Cell Transplantation Unit, Velkey László Children's Health Center, Miskolc, Hungary.
Ágnes KelemenHemato-Oncology and Stem Cell Transplantation Unit, Velkey László Children's Health Center, Miskolc, Hungary.
Endre SebestyénHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Zsuzsanna JakabHungarian Childhood Cancer Registry, Hungarian Pediatric Oncology Network, Budapest, Hungary.
András MatolcsyHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Csongor KissDivision of Pediatric Hematology-Oncology, Institute of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Gábor KovácsDepartment of Pediatrics, Semmelweis University, Budapest, Hungary.
Suvi SavolaMRC Holland, Amsterdam, The Netherlands.
Csaba BödörHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Donát AlpárHCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. alpar.donat@med.semmelweis-univ.hu.ORCID 0000-0002-2638-5418
Semmelweis University · HUUniversity of Pecs · HUMRC Holland (Netherlands) · NLUnified Szent István and Szent László Hospital · HUUniversity of Debrecen · HUHeim Pál Országos Gyermekgyógyászati Intézet · HUUniversity of Szeged · HUNational Center for Epidemiology · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecurrent genetic lesions provide basis for risk assessment in pediatric acute lymphoblastic leukemia (ALL). However, current prognostic classifiers rely on a limited number of predefined sets of alterations.

methodsDisease-relevant copy number aberrations (CNAs) were screened genome-wide in 260 children with B-cell precursor ALL. Results were integrated with cytogenetic data to improve risk assessment.

resultsCNAs were detected in 93.8% (n = 244) of the patients. First, cytogenetic profiles were combined with IKZF1 status (IKZF1

conclusionsPersonALL, our conceptually novel prognostic classifier considers all combinations of co-segregating genetic alterations, providing a highly personalized patient stratification.

Indexed as

Burkitt LymphomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaChildGene DeletionHumansIkaros Transcription FactorPrognosisRisk AssessmentIkaros Transcription Factor

Identifiers

PMID37340093
PMCPMC10403542
OpenAlexW4381470506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.